Thermo Fisher Scientific

Early collaboration and open communication between upstream and downstream are crucial to ensure a consistent end-to-end bioprocess.

The Medicine Maker speaks with Michel Legarde, President of Pharmaceutical Services, Patheon, part of Thermo Fisher Scientific.

Intensifying or simplifying your bioprocess can mean more product, shorter manufacturing times, or lower costs.

How to develop a robust and consistent bioprocess.

The development of an optimized bioprocess requires a holistic approach tailored to the specific needs of the product.

Incremental improvements to ultra-high performance liquid chromatography (UHPLC) have failed to deliver the tangible advances that researchers really want. Sometimes, a full overhaul by re-engineering from the bottom-up is the only way to innovate and move the field forward.

In-depth analysis of original and new candidate drugs for biosimilars is easier than ever before…

New technologies for extractables and leachables testing of small molecules and biopharmaceuticals.

We talk to Jasna Peter-Katalinic – a pioneer of the field - about her life in glycan analysis.

Glycan analysis poses major challenges for the biopharma industry; how can new technology lighten the load?